Evidence-based risk stratification to target therapies in acute coronary syndromes

Circulation

Volumn 106, Issue 13, 2002, Pages 1588-1591

  Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angina; Anticoagulants; Catheterization; Editorials; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; PLACEBO; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; INHIBITION KINETICS; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVASCULARIZATION; RISK ASSESSMENT; RISK MANAGEMENT; SIDE EFFECT; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA PECTORIS; ANTICOAGULANTS; BIOLOGICAL MARKERS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; ENOXAPARIN; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEART CATHETERIZATION; HUMANS; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TICLOPIDINE; TROPONIN;

EID: 0037167699     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000030416.80014.F4     Document Type: Editorial

References (41)

1. Cannon CP. Braunwald E. Unstable angina. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia, Pa: W.B. Saunders; 2001:1232-1263.
2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Unstable Angina). Available at: www.acc.org. Accessed March 15. 2002.
3. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10. Rockville, Md: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services; 1994.
4. Lindahl B, Venge P, Wallentin L, and the FRISC study group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol, 1997:29:43-48.
5. Cohen M, Antman EM, Gurfinkel EP, et al. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. J Thromb Thrombolysis. 2001;12:199-206.
6. Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI 11B substudy. J Am Coll Cardiol. 2000;36:1812-1817.
7. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835-842.
8. Sabatine MS, McCabe CH, Morrow DA, et al. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 2002;143:966-970.
9. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999;340:1623-1629.
10. Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999;354:1757-1762.
11. Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation. 2001;103:2891-2896.
12. Januzzi JL, Chai CU, Sabatine MS, et al. Elevation in serum troponin I predicts the benefit of tirofiban. J Thromb Thrombolysis. 2001;11:211-215.
13. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-st elevation acute coronary syndromes: Application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23:223-229.
14. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponin I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405-2412.
15. Cannon CP. Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
16. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107-2113.
17. Samaha FF, Kimmel SE, Goyal A, et al. TIMI risk score predicts both 30 day and 1-year outcomes for high- and low-risk stratification of non-Q-wave infarction from the VANQWISH trial. Circulation. 2001;104(suppl II):II-697. Abstract.
18. Diderholm E, Andren B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J. 2002;143:760-767.
19. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs, and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
20. Roffi M, Chew DP, Mukherjee D. et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767-2771.
21. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary synromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 1999;83:1147-1151.
22. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998:31:1460-1465.
23. Lindahl B, Toss H, Siegbahn A, et al, for the FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Markers of myoardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000;343:1139-1147.
24. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simulaneous assessment of troponin I, C-reactive protein, and B-type natriretic peptide. Circulation. 2002;105:1760-1763.
25. Scirica BM, Cannon CP, Antman EM, et al. Validation of the Thromolysis in Myocardial Infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III Registry. Am J Cardiol. In press.
26. Bartholomew BA, Sheps DS, Monroe S, et al. A prospective validation of the TIMI Risk Score (TIMI-RS) for unstable angina and non-ST-elevation myocardial infarction. Circulation. 2001;104 (suppl II):II-728. Abstract.
27. Cannon CP. Palm Pilot programs to improve the quality of care for patients with acute coronary syndromes. Crit Path Cardiol. 2002;1:113-115.
28. Budaj A, Yusuf S. Mehta SR, et al. The benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622-1626.
29. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets. 2001;12:443-447.
30. Cannon CP, on behalf of the CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol. In press.
31. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myoardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71-86.
32. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early 11 trial substudy. Circulation. 2000;102:2031-2037.
33. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME 11 substudy. Lancet. 2001;358:1571-1575.
34. Califf RM, Woodlief LH, Harrell FE Jr, et al. Selection of thrombolytic therapy for individual patients: development of a clinical model. Am Heart J. 1997;133:630-639.
35. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation. 2000;101:2557-2567.
36. Selker HP, Griffith JL, Beshansky JR, et al. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med. 1997;127:538-556.
37. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel 111). JAMA. 2001;285:2486-2497.
38. Ridker PM. Cushman M. Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
39. Ridker PM. Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
40. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial hemorrhage during thrombolytic therapy. Lancet. 1993:342:1523-1528.
41. Topol EJ, McCarthy J, Gabriel S, et al, Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001;104:2641-2644.